• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Maney Rochelle L. returned $4,539 worth of shares to the company (214 units at $21.21), decreasing direct ownership by 1% to 14,108 units

    11/5/21 4:30:04 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care
    Get the next $CRY alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Maney Rochelle L.

    (Last) (First) (Middle)
    1655 ROBERTS BLVD., NW

    (Street)
    KENNESAW GA 30144

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CRYOLIFE INC [ CRY ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    VP, Quality
    3. Date of Earliest Transaction (Month/Day/Year)
    11/04/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/04/2021 11/04/2021 D 214(1) D $21.21 14,108 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represent shares of restricted stock that were withheld for taxes on the grant vest date.
    /s/ Rochelle Maney 11/05/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CRY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRY

    DatePrice TargetRatingAnalyst
    1/7/2022$29.00 → $25.00Equal-Weight
    Morgan Stanley
    7/30/2021$31.00 → $32.00Equal-Weight
    Morgan Stanley
    7/30/2021$38.00 → $39.00Buy
    Needham
    7/15/2021$31.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $CRY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CryoLife Announces Corporate Rebranding and Changes Name to Artivion

    ATLANTA, Jan. 18, 2022 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Derived from the words "aorta", "innovation", and "vision", the company's new name and brand reflect its evolution to focus on providing innovative technologies to surgeons who treat patients with aortic disease. In conjunction with these changes, effective January 24, 2022, the company will also change its ticker symbol on the New York Stock Exchange to "AORT" from "CRY."

    1/18/22 8:10:00 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum

    ATLANTA, Nov. 9, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that members of management will host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on Thursday, November 18, 2021. Due to the format of this event no webcast will be available. For more information on the company, please visit CryoLife's website, www.cryolife.com, on the Investor Relations page. About CryoLife, Inc.Headquartered in suburban Atlanta, Georgia,

    11/9/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife Reports Third Quarter 2021 Financial Results

    ATLANTA, Nov. 4, 2021 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis Net income was $10.6 million, or $0.26 per share, in the third quarter of 2021 Non-GAAP net loss was ($1.2) million, or ($0.03) per share, in the third quarter of 2021CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its fina

    11/4/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley reiterated coverage on Cryolife with a new price target

    Morgan Stanley reiterated coverage of Cryolife with a rating of Equal-Weight and set a new price target of $25.00 from $29.00 previously

    1/7/22 8:57:55 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    Morgan Stanley reiterated coverage on Cryolife with a new price target

    Morgan Stanley reiterated coverage of Cryolife with a rating of Equal-Weight and set a new price target of $32.00 from $31.00 previously

    7/30/21 11:55:50 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    Needham reiterated coverage on Cryolife with a new price target

    Needham reiterated coverage of Cryolife with a rating of Buy and set a new price target of $39.00 from $38.00 previously

    7/30/21 6:09:23 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Horton Amy sold $46,422 worth of shares (2,500 units at $18.57) and gifted 1,500 shares, decreasing direct ownership by 4% to 85,282 units

    4 - CRYOLIFE INC (0000784199) (Issuer)

    12/10/21 4:13:01 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Davis John E bought $10,398 worth of shares (600 units at $17.33), increasing direct ownership by 0.83% to 72,499 units

    4 - CRYOLIFE INC (0000784199) (Issuer)

    12/1/21 4:14:23 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Semedo Anthony B. was granted 4,992 shares and bought $260,400 worth of shares (15,000 units at $17.36)

    4 - CRYOLIFE INC (0000784199) (Issuer)

    11/30/21 4:40:44 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Leadership Updates

    Live Leadership Updates

    View All

    Anthony Semedo Joins CryoLife Board of Directors

    ATLANTA, Sept. 22, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today the appointment of Anthony "Tony" Semedo to its Board of Directors effective October 1, 2021. "We are thrilled to welcome Tony, a leader in the aortic space, to our board of directors," commented Pat Mackin, Chairman, President, and Chief Executive Officer. "Tony's demonstrated ability to lead, grow, and integrate diversified global divisions in the medical device space as well as his experience managing robust R&D, quali

    9/22/21 4:25:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Financials

    Live finance-specific insights

    View All

    CryoLife Reports Third Quarter 2021 Financial Results

    ATLANTA, Nov. 4, 2021 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis Net income was $10.6 million, or $0.26 per share, in the third quarter of 2021 Non-GAAP net loss was ($1.2) million, or ($0.03) per share, in the third quarter of 2021CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its fina

    11/4/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2021 Financial Results

    ATLANTA, Oct. 20, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2021 financial results will be released on Thursday, November 4, 2021 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc. To participate in the conference call dial 862-298-0702 a few minutes

    10/20/21 4:10:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife Reports Second Quarter 2021 Financial Results

    ATLANTA, July 29, 2021 /PRNewswire/ -- Second Quarter and Recent Business Highlights: Achieved total revenues of $76.1 million in the second quarter 2021 versus $53.8 million in the second quarter of 2020, an increase of 42% on a GAAP basis and 35% on a non-GAAP proforma constant currency basis Net loss was ($2.2) million, or ($0.06) per share, in the second quarter of 2021 Non-GAAP net income was $4.8 million, or $0.12 per share, in the second quarter of 2021 CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today i

    7/29/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - CRYOLIFE INC (0000784199) (Subject)

    2/12/21 8:48:51 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed

    SC 13G - CRYOLIFE INC (0000784199) (Subject)

    2/11/21 2:02:44 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - CRYOLIFE INC (0000784199) (Subject)

    2/10/21 10:46:47 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    SEC Filings

    View All

    CryoLife Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - ARTIVION, INC. (0000784199) (Filer)

    1/20/22 4:36:16 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form 8-A12B/A filed by CryoLife, Inc. (Amendment)

    8-A12B/A - CRYOLIFE INC (0000784199) (Filer)

    1/6/22 11:45:40 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - CRYOLIFE INC (0000784199) (Filer)

    1/4/22 3:58:05 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care